Anthem Blue Cross and Blue Shield | CommercialOctober 31, 2023
Clinical Criteria updates for specialty pharmacy are available
Effective for dates of service on and after February 1, 2024, the following Clinical Criteria were developed and might result in services that were previously covered but may now be found to be no longer medically necessary.
For Anthem Blue Cross and Blue Shield and our affiliate HealthKeepers, Inc., prior authorization of these specialty pharmacy drugs will be managed by Anthem. Drugs used for the treatment of Oncology will still require prior authorization by Carelon Medical Benefits Management, Inc., a separate company. This applies to members with Preferred Provider Organization (PPO), and Anthem HealthKeepers (HMO).
Access the Clinical Criteria document information.
Clinical Criteria | Description |
CC-0041 | Complement Inhibitors |
CC-0119 | Yervoy (ipilimumab) |
CC-0125 | Opdivo (nivolumab) |
CC-0193 | Evkeeza (evinacumab) |
CC-0197 | Jemperli (dostarlimab-gxly) |
CC-0207 | Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-gvfc) |
CC-0243 | Vyjuvek (beremagene geperpavec) |
CC-0247 | Beyfortus (nirsevimab) |
Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan.
VABCBS-CM-040852-23
PUBLICATIONS: November 2023 Provider Newsletter
To view this article online:
Or scan this QR code with your phone